ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncol...(one or 22% for capecitabine in combinati...),Health

"This CoFactor data is encouraging to us as it surpasses the most recently reported response rates with capecitabine in pretreated advanced breast cancer patients. CoFactor plus 5-FU could be an effective and safe treatment option for patients with pretreated advanced breast cancer with the potential for further improvements to be shown with appropriate combination therapies," stated Evan M. Levine, Chief Executive Officer and President of ADVENTRX. "We look forward to evaluating all of the available data from the rest of our CoFactor program, and following analysis of these data we should have greater insight into the value of continuing to develop CoFactor," added Mr. Levine.

The most common adverse events in this study were expected and included the following, which reflects all grades: asthenia (52%), nausea (33%), diarrhea (29%), vomiting (26%), anorexia (23%), dyspnea (23%), and neutropenia (23%). Five patients reported 12 serious adverse events (pneumonia, abdominal pain, diarrhea (2), general physical health deterioration (3), pancytopenia, breast pain, dyspnea, asthenia, and hypersensitivity). Patients in this study will continue to be followed for other efficacy and safety parameters.

The Company's Phase 2 clinical trial was a single arm, multicenter study designed to evaluate the safety and efficacy of treatment with CoFactor/5-FU utilizing a bolus administration in patients with advanced breast cancer who have failed anthracycline and taxane chemotherapies with clearly defined criteria. The primary endpoint for the study is assessing objective response rate as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. RECIST criteria is a series of formalized rules for the measurement of tumor target lesions and involves techniques which measure tumor response using X-rays, CT and MRI scans. Objective response rate is measured by combining the number of comple
'/>"/>